Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair®)
Authors:
- 1 July 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 43 (5) , 573-576
Abstract
Omalizumab (Xolair((R))) is an anti-IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.Keywords
This publication has 10 references indexed in Scilit:
- Positive CD63 Basophil Activation Tests Are Common in Children with Chronic Spontaneous Urticaria and Linked to High Disease ActivityInternational Archives of Allergy and Immunology, 2016
- Current approach to cutaneous mastocytosis in childhoodTurkish Archives of Pediatrics, 2016
- Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosisAllergy, 2016
- Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical ImmunologyJournal of Allergy and Clinical Immunology, 2016
- Omalizumab as a Desensitizing Agent and Treatment in Mastocytosis: A Review of the Literature and Case ReportThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- Short-term omalizumab treatment in an adolescent with cutaneous mastocytosisAnnals of Allergy, Asthma & Immunology, 2013
- Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four CasesInternal Medicine, 2011
- Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapyJournal of Allergy and Clinical Immunology, 2007
- Diagnostic Value of Tryptase in Anaphylaxis and MastocytosisImmunology and Allergy Clinics of North America, 2006
- Monitoring human basophil activation via CD63 monoclonal antibody 435Journal of Allergy and Clinical Immunology, 1991